1-(5-t-butyl-2-furyl)-2,2-dimethylpropan-1-one | 77769-62-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(5-t-butyl-2-furyl)-2,2-dimethylpropan-1-one
• 英文别名: 1-(5-(tert-butyl)furan-2-yl)-2,2-dimethylpropan-1-one；1-(5-Tert-butylfuran-2-yl)-2,2-dimethylpropan-1-one
• CAS: 77769-62-1
• 化学式: C₁₃H₂₀O₂
• 分子量: 208.301
• InChiKey: XNRQZKXODHVFNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  三甲基乙酰氯 在 二叔丁基过氧化物 、 zinc(II) oxide 、 iron(II) chloride 作用下， 以 氟苯 、 二氯甲烷 为溶剂， 反应 24.25h， 生成 1-(5-t-butyl-2-furyl)-2,2-dimethylpropan-1-one
  参考文献：
  名称：

  铁取代的呋喃与脂肪族醛作为烷基化剂的铁催化氧化脱羰α-烷基化反应。

  摘要：

  已经开发出使用烷基醛作为烷基化剂的FeCl 2催化酰基呋喃的氧化脱羰基α-烷基化的方案。该方案以实用和可持续的方式提供中等至良好收率的α-烷基-α-酰基呋喃。机理研究表明，该反应是通过由烷基醛生成烷基，将自由基加至呋喃环并随后进行重新芳构化来进行的。

  DOI：

  10.1021/acs.joc.0c01002

文献信息

• KINASE INHIBITORS AND METHODS FOR MAKING AND USING
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20190002455A1

  公开（公告）日：2019-01-03

  Disclosed embodiments concern kinase inhibitors, such as interleukin receptor associated kinases (IRAK) inhibitors, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.

  披露的实施例涉及激酶抑制剂，例如白细胞介素受体相关激酶（IRAK）抑制剂，以及包含此类抑制剂的组合物。还披露了制备和使用这些化合物和组合物的方法。所披露的化合物和/或组合物可用于治疗或预防激酶相关疾病或症状，特别是IRAK相关的疾病或症状。
• Kinase inhibitors and methods for making and using
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US10590121B2

  公开（公告）日：2020-03-17

  Disclosed embodiments concern kinase inhibitors having a structure according to formula 1, such as interleukin receptor associated kinases (IRAK) inhibitors, and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent a kinase-associated disease or condition, particularly an IRAK-associated disease or condition.

  所公开的实施方案涉及具有根据式 1 所述结构的激酶抑制剂，如白细胞介素受体相关激酶（IRAK）抑制剂，以及包含此类抑制剂的组合物。 还公开了制造和使用这些化合物和组合物的方法。所公开的化合物和/或组合物可用于治疗或预防激酶相关疾病或病症，尤其是 IRAK 相关疾病或病症。
• Sjoeholm, Rainer; Woerlund, Krister, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry, 1980, vol. 34, # 6, p. 435 - 442
  作者：Sjoeholm, Rainer、Woerlund, Krister

  DOI：——

  日期：——
• SJOHOLM R.; WORLUND K., ACTA CHEM. SCAND., 1980, B34, NO 6, 435-441
  作者：SJOHOLM R.、 WORLUND K.

  DOI：——

  日期：——
• METHODS OF ANALYZING POLYNUCLEOTIDES EMPLOYING ENERGY TRANSFER DYES
  申请人：Lee G. Linda

  公开号：US20070154925A1

  公开（公告）日：2007-07-05

  Novel linkers for linking a donor dye to an acceptor dye in an energy transfer fluorescent dye are provided. These linkers faciliate the efficient transfer of energy between a donor and acceptor dye in an energy transfer dye. One of these linkers for linking a donor dye to an acceptor dye in an energy transfer fluorescent dye has the general structure R 21 Z 1 C(O)R 22 R 28 where R 21 is a C 1-5 alkyl attached to the donor dye, C(O) is a carbonyl group, Z 1 is either NH, sulfur or oxygen, R 22 is a substituent which includes an alkene, diene, alkyne, a five and six membered ring having at least one unsaturated bond or a fused ring structure which is attached to the carbonyl carbon, and R 28 includes a functional group which attaches the linker to the acceptor dye.